NEI to test Lucentis and Avastin for treating eye disorder

10/2/2006 | Bloomberg

The National Eye Institute may test Genentech's eye drug Lucentis and its cancer drug Avastin to compare the two in treating age-related macular degeneration. However, the institute said some major funding issues remain in creating the trial.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA